The price of Spero Therapeutics Inc. (NASDAQ:SPRO) shares last traded on Wall Street unchanged to $1.55.
SPRO stock price is now -16.40% away from the 50-day moving average and -34.49% away from the 200-day moving average. The market capitalization of the company currently stands at $80.23M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
With the price target enhanced from $2 to $8, Evercore ISI Upgraded its rating from In-line to Outperform for Spero Therapeutics Inc. (NASDAQ: SPRO)., while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
In other news, Aquilo Capital Management, LLC, 10% Owner sold 1,901,796 shares of the company’s stock on Sep 22. The stock was sold for $4,279,612 at an average price of $2.25. Upon completion of the transaction, the 10% Owner now directly owns 3,419,435 shares in the company, valued at $5.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 29, Chief Financial Officer Shukla Sath sold 6,017 shares of the business’s stock. A total of $5,378 was realized by selling the stock at an average price of $0.89. This leaves the insider owning 56,064 shares of the company worth $86899.2. Insiders disposed of 1,907,813 shares of company stock worth roughly $2.96 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SPRO stock. A new stake in Spero Therapeutics Inc. shares was purchased by AWM INVESTMENT COMPANY, INC. during the first quarter worth $3,566,000. ANSON FUNDS MANAGEMENT LP invested $2,285,000 in shares of SPRO during the first quarter. In the first quarter, MURCHINSON LTD. acquired a new stake in Spero Therapeutics Inc. valued at approximately $1,182,000. BANK OF MONTREAL /CAN/ acquired a new stake in SPRO for approximately $314,000. DAFNA CAPITAL MANAGEMENT LLC purchased a new stake in SPRO valued at around $194,000 in the second quarter. In total, there are 103 active investors with 38.70% ownership of the company’s stock.
A candlestick chart of Spero Therapeutics Inc. (NASDAQ: SPRO) showed a price of $1.5500 on Wednesday morning. During the past 12 months, Spero Therapeutics Inc. has had a low of $0.68 and a high of $16.30. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.30, and a quick ratio of 3.30. The fifty day moving average price for SPRO is $1.8540 and a two-hundred day moving average price translates $2.3662 for the stock.
The latest earnings results from Spero Therapeutics Inc. (NASDAQ: SPRO) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.87, beating analysts’ expectations of -$0.93 by 0.06. This compares to -$0.70 EPS in the same period last year. The company reported revenue of $2.01 million for the quarter, compared to $3.06 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -34.53 percent. For the current quarter, analysts expect SPRO to generate $5.42M in revenue.
Spero Therapeutics Inc.(SPRO) Company Profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
